Interviews

Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

Andrew Yee, MD, explains how academic centers can share practical oncology best practices that community hospitals can implement sustainably.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

Community-academic collaboration can reduce access burdens and strengthen continuity of care, says Anasuya Gunturi, MD, PhD.

Osama Abdelghany, PharmD, explains how medically integrated dispensing improves oncology workflows, patient access, and outcomes through EMR-driven care.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

Catchment areas, access, and partnerships influence diversity in oncology trials, Amir Fathi, MD, explains at a Boston IVBM panel.

Medically integrated dispensing improves oncology treatment coordination through EMR-based care, but payer restrictions remain a key barrier.

Medically integrated dispensing is well-positioned to support value-based oncology care models and closer patient follow-up and monitoring, says Katherine Tobon, PharmD, BCOP.

MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.

Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

Jose Guzman Garcia, PharmD, MHA, BCCCP, discusses key pharmacy initiatives at UC Davis Health.

Bhavana (Tina) Bhatnagar, DO, discusses the transformative role of AI in enhancing patient care at West Virginia University Cancer Institute.

Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care systems, explains Adam Brufsky, MD, PhD.

Danielle Roman, PharmD, BCOP, explains why a collaborative, team-based approach is essential to solving resource challenges in community cancer care.

Prerna Mewawalla, MD, discusses innovative strategies to enhance cancer care access, reduce clinician burden, and improve clinical trial diversity in real-world settings.

Despite the impact of targeted treatment in oncology, much work remains to bring these therapeutics to all patients, says Bhavana (Tina) Bhatnagar, DO.

Kavita Nair, PhD, FAAN, shares how new therapies and ongoing clinical trials are reshaping the future of neurological care and offering new hope to patients.

Michael Hassett, MD, explains the evolving landscape of HER2-positive breast cancer treatment and the role of CDK inhibition in personalized therapy strategies.

Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.

Kavita Nair, PhD, FAAN, discusses academic medical centers' unique role in diagnosing and managing neurodegenerative diseases.

Jasmine Eugene, PharmD, explains how pharmacists practicing at the top of their license improve rural oncology access and ease physician workload.